Biotech and medtech companies must prioritize intellectual property (IP) security, as weak security can deter investors and jeopardize deals. Effective controls enhance fundraising, partnerships, and regulatory compliance. Investors increasingly value companies that demonstrate strong security measures, making it vital for early-stage firms to integrate these practices to remain competitive and attract funding. Continue reading →